Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer.

BACKGROUND Positron emission tomography and computed tomography (PET/CT) have a potential role in detecting and locating recurrent ovarian cancer. Precise tumor location during surgical treatment is often difficult, owing to limited tumor size and post-surgical anatomic modifications. The surgical gamma probe, which has become increasing popular in recent years with the development of sentinel node mapping, may improve tumor detection and facilitate resection of occult metastases. CASE REPORT We describe the first case of laparoscopic resection of occult metastasis using the combination of FDG-PET/CT image fusion with intraoperative FDG-sensitive probing in a patient with recurrent ovarian cancer. CONCLUSION FDG-sensitive probe combined with preoperative PET/CT image fusion can help to detect occult metastasis and guide laparoscopic excision.

[1]  R. Essner,et al.  Application of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. , 2001, The Journal of surgical research.

[2]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[3]  R. Wahl,et al.  PET-CT in recurrent ovarian cancer: initial observations. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[4]  K. Togashi,et al.  Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. , 2001, AJR. American journal of roentgenology.

[5]  E. Martin,et al.  18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer: a feasibility study. , 2001, The Journal of surgical research.

[6]  Elliot K Fishman,et al.  Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. , 2003, Gynecologic oncology.

[7]  E. Darai,et al.  Laparoscopic sentinel lymph node procedure using a combination of patent blue and radioisotope in women with cervical carcinoma , 2003, Cancer.

[8]  S. Rubin,et al.  Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. , 1989 .

[9]  J S Karp,et al.  Performance of a whole-body PET scanner using curve-plate NaI(Tl) detectors. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  C. Meltzer,et al.  Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. , 2002, Gynecologic Oncology.

[11]  E. Yoshikawa,et al.  Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  E. Yordan,et al.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. V. von Schulthess,et al.  Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma , 2000, European Radiology.

[14]  E. Martin,et al.  Correlative Whole-Body FDG-PET and Intraoperative Gamma Detection of FDG Distribution in Colorectal Cancer. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[15]  R. Bast,et al.  Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. , 1985, American journal of obstetrics and gynecology.

[16]  M. Deavers,et al.  Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.